{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:21:48Z","timestamp":1778170908508,"version":"3.51.4"},"reference-count":57,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001821","name":"Vienna Science and Technology Fund","doi-asserted-by":"publisher","award":["CS 15-033"],"award-info":[{"award-number":["CS 15-033"]}],"id":[{"id":"10.13039\/501100001821","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"FWF Austrian Science Fund","doi-asserted-by":"publisher","award":["W1232"],"award-info":[{"award-number":["W1232"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"FWF Austrian Science Fund","doi-asserted-by":"publisher","award":["DOC33-B27"],"award-info":[{"award-number":["DOC33-B27"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Theodor K\u00f6rner Fonds","award":["2020"],"award-info":[{"award-number":["2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Many psychoactive compounds have been shown to primarily interact with high-affinity and low-capacity solute carrier 6 (SLC6) monoamine transporters for norepinephrine (NET; norepinephrine transporter), dopamine (DAT; dopamine transporter) and serotonin (SERT; serotonin transporter). Previous studies indicate an overlap between the inhibitory capacities of substances at SLC6 and SLC22 human organic cation transporters (SLC22A1\u20133; hOCT1\u20133) and the human plasma membrane monoamine transporter (SLC29A4; hPMAT), which can be classified as high-capacity, low-affinity monoamine transporters. However, interactions between central nervous system active substances, the OCTs, and the functionally-related PMAT have largely been understudied. Herein, we report data from 17 psychoactive substances interacting with the SLC6 monoamine transporters, concerning their potential to interact with the human OCT isoforms and hPMAT by utilizing radiotracer-based in vitro uptake inhibition assays at stably expressing human embryonic kidney 293 cells (HEK293) cells. Many compounds inhibit substrate uptake by hOCT1 and hOCT2 in the low micromolar range, whereas only a few substances interact with hOCT3 and hPMAT. Interestingly, methylphenidate and ketamine selectively interact with hOCT1 or hOCT2, respectively. Additionally, 3,4-methylenedioxymethamphetamine (MDMA) is a potent inhibitor of hOCT1 and 2 and hPMAT. Enantiospecific differences of R- and S-\u03b1-pyrrolidinovalerophenone (R- and S-\u03b1-PVP) and R- and S-citalopram and the effects of aromatic substituents are explored. Our results highlight the significance of investigating drug interactions with hOCTs and hPMAT, due to their role in regulating monoamine concentrations and xenobiotic clearance.<\/jats:p>","DOI":"10.3390\/ijms222312995","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T22:01:11Z","timestamp":1638309671000},"page":"12995","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Interaction Profiles of Central Nervous System Active Drugs at Human Organic Cation Transporters 1\u20133 and Human Plasma Membrane Monoamine Transporter"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6119-0472","authenticated-orcid":false,"given":"Thomas J. F.","family":"Angenoorth","sequence":"first","affiliation":[{"name":"Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, W\u00e4hringerstra\u00dfe 13A, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stevan","family":"Stankovic","sequence":"additional","affiliation":[{"name":"Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, W\u00e4hringerstra\u00dfe 13A, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0518-5791","authenticated-orcid":false,"given":"Marco","family":"Niello","sequence":"additional","affiliation":[{"name":"Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, W\u00e4hringerstra\u00dfe 13A, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Holy","sequence":"additional","affiliation":[{"name":"Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, W\u00e4hringerstra\u00dfe 13A, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8632-5372","authenticated-orcid":false,"given":"Simon D.","family":"Brandt","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-7444","authenticated-orcid":false,"given":"Harald H.","family":"Sitte","sequence":"additional","affiliation":[{"name":"Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, W\u00e4hringerstra\u00dfe 13A, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6016-1947","authenticated-orcid":false,"given":"Julian","family":"Maier","sequence":"additional","affiliation":[{"name":"Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, W\u00e4hringerstra\u00dfe 13A, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.bjp.0704785","article-title":"Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3","volume":"136","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"ref_2","first-page":"1","article-title":"The Interaction of Organic Cation Transporters 1-3 and PMAT with Psychoactive Substances","volume":"3","author":"Maier","year":"2021","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/164_2021_470","article-title":"Organic Cation Transporters in Brain Catecholamine Homeostasis","volume":"Volume 266","author":"Gasser","year":"2021","journal-title":"Handbook of Experimental Pharmacology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7902","DOI":"10.1128\/MCB.23.21.7902-7908.2003","article-title":"Deficiency in the Organic Cation Transporters 1 and 2 (Oct1\/Oct2 [Slc22a1\/Slc22a2]) in Mice Abolishes Renal Secretion of Organic Cations","volume":"23","author":"Jonker","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.103.053298","article-title":"Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3)","volume":"308","author":"Jonker","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11095-007-9254-z","article-title":"Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications","volume":"24","author":"Koepsell","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1089\/dna.1997.16.871","article-title":"Cloning and characterization of two human polyspecific organic cation transporters","volume":"16","author":"Gorboulev","year":"1997","journal-title":"DNA Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1471-4159.2008.05506.x","article-title":"Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice","volume":"106","author":"Vialou","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2014.09.008","article-title":"Role of organic cation transporters (OCTs) in the brain","volume":"146","author":"Gautron","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/cn3001872","article-title":"Revisiting serotonin reuptake inhibitors and the therapeutic potential of \u201cuptake-2\u201d in psychiatric disorders","volume":"4","author":"Daws","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/cpt.442","article-title":"The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition","volume":"100","author":"Wang","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/00498250701882482","article-title":"Organic cation transporters","volume":"38","author":"Ciarimboli","year":"2008","journal-title":"Xenobiotica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ejphar.2018.10.028","article-title":"Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter","volume":"842","author":"Basiouny","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1021\/mp400024d","article-title":"Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3","volume":"10","author":"Li","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tips.2014.11.006","article-title":"Amphetamines, new psychoactive drugs and the monoamine transporter cycle","volume":"36","author":"Sitte","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00210-012-0781-8","article-title":"Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3","volume":"385","author":"Haenisch","year":"2012","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2020.609811","article-title":"Cellular Uptake of Psychostimulants\u2013Are High- and Low-Affinity Organic Cation Transporters Drug Traffickers?","volume":"11","author":"Jensen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00424-013-1335-8","article-title":"The organic cation transporter 3 (OCT3) as molecular target of psychotropic drugs: Transport characteristics and acute regulation of cloned murine OCT3","volume":"466","author":"Massmann","year":"2014","journal-title":"Pflugers Arch. Eur. J. Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1038\/s41386-018-0053-5","article-title":"An unsuspected role for organic cation transporter 3 in the actions of amphetamine","volume":"43","author":"Mayer","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/clpt.2011.56","article-title":"Genetically polymorphic OCT1: Another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol","volume":"90","author":"Tzvetkov","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bcp.2006.09.008","article-title":"Evidence for significant contribution of a newly identified monoamine transporter (PMAT) to serotonin uptake in the human brain","volume":"73","author":"Zhou","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"108570","DOI":"10.1016\/j.neuropharm.2021.108570","article-title":"\u03b1-PPP and its derivatives are selective partial releasers at the human norepinephrine transporter: A pharmacological characterization of interactions between pyrrolidinopropiophenones and uptake1 and uptake2 monoamine transporters","volume":"190","author":"Maier","year":"2021","journal-title":"Neuropharmacology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1021\/acschemneuro.8b00415","article-title":"DARK Classics in Chemical Neuroscience: Aminorex Analogues","volume":"9","author":"Maier","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bcp.2013.06.019","article-title":"Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration","volume":"86","author":"Tzvetkov","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1124\/pr.118.015578","article-title":"Organic cation transporters in health and disease","volume":"72","author":"Koepsell","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.neuropharm.2006.01.005","article-title":"Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain","volume":"50","author":"Amphoux","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/FPC.0b013e32832cc7e9","article-title":"Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin","volume":"19","author":"Chen","year":"2009","journal-title":"Pharmacogenetics Genom."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1146\/annurev-pharmtox-010617-052713","article-title":"The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease","volume":"58","author":"Nigam","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cpt.941","article-title":"Emerging Clinical Importance of Hepatic Organic Cation Transporter 1 (OCT1) in Drug Pharmacokinetics, Dynamics, Pharmacogenetic Variability, and Drug Interactions","volume":"103","author":"Giacomini","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_30","first-page":"1","article-title":"Drug-Drug Interactions at Organic Cation Transporter 1","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/FPC.0000000000000048","article-title":"PharmGKB summary: Very important pharmacogene information for SLC22A1","volume":"24","author":"Goswami","year":"2014","journal-title":"Pharmacogenetics Genom."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1124\/mol.104.001313","article-title":"Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors","volume":"66","author":"Damaj","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acschemneuro.6b00358","article-title":"Diazepam Inhibits Electrically Evoked and Tonic Dopamine Release in the Nucleus Accumbens and Reverses the Effect of Amphetamine","volume":"8","author":"Fiorenza","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/jpet.106.106583","article-title":"Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro","volume":"319","author":"Madras","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.euroneuro.2014.12.012","article-title":"Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones","volume":"25","author":"Rickli","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(97)01393-9","article-title":"Pharmacological profile of antidepressants and related compounds at human monoamine transporters","volume":"340","author":"Tatsumi","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mato, E.P.M., Guewo-Fokeng, M., Faadiel Essop, M., and Owira, P.M.O. (2018). Genetic polymorphisms of organic cation transporters 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes mellitus: A systematic review protocol. Syst. Rev., 7.","DOI":"10.1186\/s13643-018-0773-y"},{"key":"ref_38","first-page":"175","article-title":"Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions","volume":"7","author":"Minuesa","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_39","unstructured":"FDA, U.S (2020, October 18). Guidance for Industry: Clinical Drug Interaction Studies\u2014Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions, Available online: https:\/\/www.fda.gov\/media\/134581\/download."},{"key":"ref_40","unstructured":"EMA (2021, November 29). Guideline on the Investigation of Drug Interactions Guideline on the Investigation of Drug Interactions. Available online: www.ema.europa.eu\/contact."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2020.00673","article-title":"Cell-Based Radiotracer Binding and Uptake Inhibition Assays: A Comparison of In Vitro Methods to Assess the Potency of Drugs That Target Monoamine Transporters","volume":"11","author":"Ilic","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1124\/mol.104.008821","article-title":"Subtype-Specific Affinity for Corticosterone of Rat Organic Cation Transporters rOCT1 and rOCT2 Depends on Three Amino Acids within the Substrate Binding Region","volume":"67","author":"Gorboulev","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1124\/mol.104.008839","article-title":"Amino Acids Critical for Substrate Affinity of Rat Organic Cation Transporter 1 Line the Substrate Binding Region in a Model Derived from the Tertiary Structure of Lactose Permease","volume":"67","author":"Popp","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/jpet.116.232660","article-title":"Molecular Properties of Drugs Interacting with SLC22 Transporters OAT1, OAT3, OCT1, and OCT2: A Machine-Learning Approachs","volume":"359","author":"Liu","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/jpet.116.236349","article-title":"Structure-activity relationships of substituted cathinones, with transporter binding, uptake, and release","volume":"360","author":"Eshleman","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Niello, M., Cintulova, D., Hellsberg, E., J\u00e4ntsch, K., Holy, M., Ayatollahi, L.H., Cozzi, N.V., Freissmuth, M., Sandtner, W., and Ecker, G.F. (2019). Para-Trifluoromethyl-methcathinone is an allosteric modulator of the serotonin transporter. Neuropharmacology, 161.","DOI":"10.1016\/j.neuropharm.2019.04.021"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3389\/fphar.2021.654061","article-title":"Effects of Hydroxylated Mephedrone Metabolites on Monoamine Transporter Activity in vitro","volume":"12","author":"Niello","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Niello, M., Sideromenos, S., Gradisch, R., O\u2019shea, R., Schwazer, J., Sandtner, W., Maier, J., J\u00e4ntsch, K., Lupica, C., and Hoffman, A. (2021). Psychomotor stimulant effects of \u03b1-pyrrolidinovalerophenone (\u03b1PVP) enantiomers correlate with drug binding kinetics at the dopamine transporter. Res. Sq., 1\u201325.","DOI":"10.21203\/rs.3.rs-612345\/v1"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1021\/jm8003152","article-title":"Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1","volume":"51","author":"Ahlin","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.tips.2020.04.006","article-title":"Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy","volume":"41","author":"Niello","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/mol.118.113498","article-title":"Rat organic cation transporter 1 contains three binding sites for substrate 1-methyl-4-phenylpyridinium per monomer","volume":"95","author":"Keller","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.neuropharm.2017.07.026","article-title":"Pharmacological profile of mephedrone analogs and related new psychoactive substances","volume":"134","author":"Luethi","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2165\/00003088-199937060-00002","article-title":"Pharmacokinetics and clinical effectiveness of methylphenidate","volume":"37","author":"Kimko","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuropharm.2018.06.018","article-title":"The psychostimulant (\u00b1)-cis-4,4\u2019-dimethylaminorex (4,4\u2019-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters","volume":"138","author":"Maier","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_55","unstructured":"(2021, November 29). jetPRIME. Available online: https:\/\/www.polyplus-transfection.com\/products\/jetprime\/."},{"key":"ref_56","unstructured":"ColorBrewer (2021, November 29). ColorBrewer: Color Advice for Maps. Available online: http:\/\/colorbrewer2.org\/."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Daws, L.C. (2021). Organic Cation Transporters in Psychiatric Disorders. Handb. Exp. Pharmacol.","DOI":"10.1007\/164_2021_473"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/23\/12995\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:38:11Z","timestamp":1760168291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/23\/12995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":57,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["ijms222312995"],"URL":"https:\/\/doi.org\/10.3390\/ijms222312995","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}